Oculis (NASDAQ:OCS) Shares Up 9.2% – Still a Buy?

Oculis Holding AG (NASDAQ:OCS)’s stock price rose 9.2% on Tuesday . The stock traded as high as $26.51 and last traded at $26.7970. Approximately 15,127 shares changed hands during trading, a decline of 95% from the average daily volume of 325,608 shares. The stock had previously closed at $24.55.

Wall Street Analyst Weigh In

Several brokerages have issued reports on OCS. Stifel Nicolaus upped their price target on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Needham & Company LLC raised their price objective on shares of Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. HC Wainwright lifted their price objective on Oculis from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. JPMorgan Chase & Co. assumed coverage on Oculis in a research note on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.86.

Oculis Price Performance

The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -11.91 and a beta of 0.48. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.01. The company’s 50 day simple moving average is $27.45 and its 200-day simple moving average is $22.69.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. On average, equities research analysts predict that Oculis Holding AG will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its position in shares of Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC purchased a new position in Oculis during the fourth quarter worth about $80,000. Millennium Management LLC acquired a new stake in Oculis in the 4th quarter worth about $312,000. Bosun Asset Management LLC acquired a new stake in Oculis in the 2nd quarter worth about $378,000. Finally, Marshall Wace LLP purchased a new stake in Oculis in the 2nd quarter valued at about $393,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.